Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.59 HKD | -0.90% | 0.00% | -12.37% |
Apr. 22 | 3Sbio Inc. Announces Management Changes | CI |
Apr. 15 | 3SBIO Gets China Nod for Use of Cancer Injection in Children with Thrombocytopenia | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- The company is in a robust financial situation considering its net cash and margin position.
- Its low valuation, with P/E ratio at 8.65 and 7.87 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The company has a low valuation given the cash flows generated by its activity.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-12.37% | 2.01B | B | ||
-1.26% | 89.46B | A- | ||
+2.76% | 40.74B | A- | ||
-8.90% | 33.03B | B- | ||
+55.32% | 24.68B | A | ||
-16.41% | 15.12B | C | ||
-8.97% | 12.81B | B- | ||
-12.11% | 11.79B | D+ | ||
-43.61% | 11.64B | B | ||
+7.79% | 8.9B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 1530 Stock
- Ratings 3SBio Inc.